N-(4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)-2-(o-toluenyloxy)ethanamide | 313483-37-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)-2-(o-toluenyloxy)ethanamide
• 英文别名: N-(4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)-2-(o-tolyloxy)acetamide；N-[4-(5-chloro-1,3-benzoxazol-2-yl)phenyl]-2-(2-methylphenoxy)acetamide
• CAS: 313483-37-3
• 化学式: C₂₂H₁₇ClN₂O₃
• 分子量: 392.842
• InChiKey: WKMYRABSTSFCBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)-2-(o-toluenyloxy)ethanamide 、 碘甲烷 在 lithium hexamethyldisilazane 作用下， 以95%的产率得到N-(4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)-N-methyl-2-(o-tolyloxy)acetamide
  参考文献：
  名称：

  2-Arylbenzoxazoles as CETP inhibitors: Substitution and modification of the α-alkoxyamide moiety

  摘要：

  The development of a series of 2-arylbenzoxazole alpha-alkoxyamide and beta-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated alpha-alkoxyamides proved to be potent inhibitors of CETP in vitro, and the highly fluorinated 2-arylbenzoxazole beta-alkoxyamine 4 showed a desirable combination of in vitro potency (IC(50) = 151 nM) and oral bioavailability in the mouse. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.046
• 作为产物：
  描述：

  2-bromo-N-[4-(5-chloro-1,3-benzoxazol-2-yl)phenyl]acetamide 、 邻甲酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(4-(5-chlorobenzo[d]oxazol-2-yl)phenyl)-2-(o-toluenyloxy)ethanamide
  参考文献：
  名称：

  2-Arylbenzoxazoles as CETP inhibitors: Substitution and modification of the α-alkoxyamide moiety

  摘要：

  The development of a series of 2-arylbenzoxazole alpha-alkoxyamide and beta-alkoxyamine inhibitors of cholesteryl ester transfer protein (CETP) is described. Highly fluorinated alpha-alkoxyamides proved to be potent inhibitors of CETP in vitro, and the highly fluorinated 2-arylbenzoxazole beta-alkoxyamine 4 showed a desirable combination of in vitro potency (IC(50) = 151 nM) and oral bioavailability in the mouse. (c) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.046

文献信息

• METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES
  申请人：DalCor Pharma UK Ltd Leatherhead, Zug Branch

  公开号：EP3833336A1

  公开（公告）日：2021-06-16
• Cetp Inhibitors
  申请人：Ali Amjad

  公开号：US20090264405A1

  公开（公告）日：2009-10-22

  Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis.
• METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS
  申请人：DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH

  公开号：US20190070178A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• [EN] METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS<br/>[FR] MÉTHODES DE TRAITEMENT OU DE PRÉVENTION DE TROUBLES CARDIOVASCULAIRES ET D'ABAISSEMENT DU RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES
  申请人：DALCOR PHARMA UK LTD STOCKPORT ZUG BRANCH

  公开号：WO2019043018A1

  公开（公告）日：2019-03-07

  The invention provides compositions and methods useful for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events.
• [EN] METHODS FOR DELAYING OCCURRENCE OF NEW-ONSET TYPE 2 DIABETES AND FOR SLOWING PROGRESSION OF AND TREATING TYPE 2 DIABETES<br/>[FR] PROCÉDÉS POUR RETARDER L'APPARITION D'UN NOUVEAU DEBUT DE DIABÈTE DE TYPE 2 DE TYPE 2 ET POUR RALENTIR LA PROGRESSION ET TRAITER LE DIABÈTE DE TYPE 2
  申请人：DALCOR PHARMA UK LTD LEATHERHEAD ZUG BRANCH

  公开号：WO2020030814A1

  公开（公告）日：2020-02-13

  The invention provides compositions and methods useful for delaying occurrence of new- onset type 2 diabetes, slowing progression of type 2 diabetes, treating type 2 diabetes, and slowing progression of a complication of type 2 diabetes.